BIODESIX INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M |
| Selling, general & administrative | $87.5M | $80.5M | $67.4M | $61.5M | $50.5M |
| Research and development | $12.0M | $9.6M | $10.0M | $13.1M | $12.8M |
| Operating expenses | $116.4M | $105.8M | $90.4M | $88.8M | $95.4M |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M |
| Interest expense | $7.7M | $8.3M | $9.5M | $8.1M | $4.5M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M |
| Balance Sheet | |||||
| Cash and equivalents | $19.0M | $26.2M | $26.3M | $43.1M | $32.7M |
| Current assets | $32.5M | $39.5M | $39.7M | $53.3M | $43.6M |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M |
| Current liabilities | $17.4M | $14.3M | $33.4M | $22.8M | $29.0M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M |
| Stockholders' equity | -$2.5M | $20.9M | $4.6M | $20.6M | $19.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M |
| Depreciation and amortization | $5.7M | $5.8M | $3.3M | $3.6M | $3.2M |
| Stock-based compensation | $4.1M | $6.6M | $5.4M | $6.0M | $4.9M |
| Capital expenditure | $259,000 | $3.2M | $22.9M | $3.3M | $2.2M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 10.1M · Free float 76.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.